METAGENOMI INC (MGX) Stock Price, Quote, News and Overview
NASDAQ:MGX - Nasdaq - US59102M1045 - Common Stock
MGX Quote and Key Statistics
METAGENOMI INC
NASDAQ:MGX (1/22/2025, 10:44:10 AM)
3.405
+0.68 (+25.18%)
MGX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.64% | ||
| ROE | -28.91% | ||
| Debt/Equity | 0 |
MGX Performance and Technical Analysis
MGX Ownership and Analysts
MGX Latest News and Analysis
Gapping stocks in Wednesday's session
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency...
Metagenomi Announces New Appointment to its Board of Directors
About MGX
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 207 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
Company Info
METAGENOMI INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 207
Company Website: https://metagenomi.co/
Phone: 15108714880
MGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 300.20B | ||
| AMGN | AMGEN INC | 14.23 | 147.04B | ||
| GILD | GILEAD SCIENCES INC | 20.78 | 114.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 841.53 | 110.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.15B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.52B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.08B | ||
| NTRA | NATERA INC | N/A | 22.49B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.73B |